国内首个抗失眠创新药法赞雷生在美团买药线上首发
Ranking
Overall
47
Content
45
Popularity
N/A
No observed public metrics; popularity remains neutral/archived.
Merged summary
TL;DR - China’s first domestically developed dual orexin receptor antagonist, fazamorexant tablets (百乐眠®), launched online through Meituan Medicine for adults with difficulty falling or staying asleep.
- The drug targets both orexin receptors as a DORA-class insomnia treatment.
- Its online debut expands digital access to a newer sleep-treatment option.
- Meituan reports double-digit compound growth in orders for DORA sleep medicines.
Sources (1)
国内首个抗失眠创新药法赞雷生在美团买药线上首发
Public signals
N/A
TL;DR - China’s first domestically developed dual orexin receptor antagonist, fazamorexant tablets (百乐眠®), launched online through Meituan Medicine for adults with difficulty falling or staying asleep.
- The drug targets both orexin receptors as a DORA-class insomnia treatment.
- Its online debut expands digital access to a newer sleep-treatment option.
- Meituan reports double-digit compound growth in orders for DORA sleep medicines.